Business Standard

Tuesday, December 24, 2024 | 01:26 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Novartis

Novartis eyes sale of listed unit in India, says Global CEO Narasimhan

Narasimhan emphasised that India remains pivotal for talent sourcing and research, despite a shift away from manufacturing

Novartis eyes sale of listed unit in India, says Global CEO Narasimhan
Updated On : 22 Mar 2024 | 8:36 PM IST

Novartis announces strategic review of Novartis India Limited

Drug major Novartis AG on Friday announced a strategic review of Novartis India Ltd, a public company listed on the BSE. The strategic review will include an assessment of the 70.68 per cent shareholding of Novartis AG in the company, the drug firm said in a statement. Novartis India Ltd is separate from Novartis Healthcare Pvt Ltd, the wholly owned subsidiary of Novartis group in India. Novartis Healthcare Pvt Ltd includes the Novartis Corporate Centre in Hyderabad, the commercial arm of Novartis in India, and R&D teams, which currently conduct clinical trials at more than 300 trial sites in the country. The strategic review will not impact Novartis Healthcare Pvt Ltd, Novartis AG stated. There can be no assurance that the strategic review of Novartis India Ltd will be completed in 2024, or that the outcome would result in the implementation of any transaction, it said. Novartis remains deeply committed to India with a footprint that has expanded significantly in recent years, i

Novartis announces strategic review of Novartis India Limited
Updated On : 16 Feb 2024 | 10:58 PM IST

JB Pharma, Novartis ink Rs 1,089 cr deal for select ophthalmology brands

JB Chemicals & Pharmaceuticals Ltd (JB Pharma)on Tuesday said it has inked a trade mark licence agreement along with promotion and distribution pact with Novartis for select ophthalmology brands entailing a total sum of Rs 1,089 crore. The board of directors at its meeting held on December 19, 2023 approved the execution of a trade mark licence agreement with Novartis Innovative Therapies AG, which is perpetual in nature for the Indian market, for a portfolio of select ophthalmology brands which will be effective in January 2027, JB Pharma said in a regulatory filing. The board also approved the promotion and distribution agreement with Novartis Healthcare Pvt Ltd for the same portfolio of select ophthalmology brands for the Indian market for a period of three years starting December 2023, it added. On the financial details of the agreements, JB Pharma said it will pay USD 116 million (Rs 964 crore), excluding applicable taxes, stamp duty and working capital, for the trade marks ..

JB Pharma, Novartis ink Rs 1,089 cr deal for select ophthalmology brands
Updated On : 19 Dec 2023 | 1:59 PM IST

Bausch + Lomb to buy dry-eye drug maker Novartis for $1.75 bn: Report

Acquisition of the drug, Xiidra, will mark the first big deal by CEO Brent Saunders since he returned to the company in March

Bausch + Lomb to buy dry-eye drug maker Novartis for $1.75 bn: Report
Updated On : 30 Jun 2023 | 5:15 PM IST

Cipla inks licensing pact with Novartis to manufacture, mkt diabetes drug

Drug major Cipla on Monday said it has inked a licensing pact with Novartis Pharma AG to manufacture and market Galvus range, used in the treatment of type 2 diabetes, from January 1, 2026. The Mumbai-based company has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market Galvus and Galvus combination brands, it said in a regulatory filing. "This deal is expected to further bolster Cipla's position in India as one of the top players in the diabetes category," it added. The agreement is subject to satisfaction of certain conditions precedent, the drug firm said. Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication category, the drug firm stated. On Monday, shares of Cipla ended 1.02 per cent up at Rs 901.85 apiece on the BSE.

Cipla inks licensing pact with Novartis to manufacture, mkt diabetes drug
Updated On : 10 Apr 2023 | 8:58 PM IST

Glenmark pharma launches generic version of Novartis' heart failure drug

Opens floodgates for more generic launches; 40 new brands expected

Glenmark pharma launches generic version of Novartis' heart failure drug
Updated On : 17 Jan 2023 | 10:51 PM IST

Breather for Natco in Novartis cardiac drug case from Delhi High Court

May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week

Breather for Natco in Novartis cardiac drug case from Delhi High Court
Updated On : 15 Jan 2023 | 9:33 PM IST

Novartis signs world's first licensing deal for high-priced cancer drug

The oral drug, nilotinib, is used to treat chronic myeloid leukemia and may be made in Egypt, Guatemala, Indonesia, Morocco, Pakistan, the Philippines, and Tunisia

Novartis signs world's first licensing deal for high-priced cancer drug
Updated On : 20 Oct 2022 | 11:55 PM IST

Novartis to cut up to 8,000 jobs globally to save $1 bn by 2024

As part of the organisational overhaul unveiled in April, Novartis said that the cost cuts would be mainly from removing overlapping structures

Novartis to cut up to 8,000 jobs globally to save $1 bn by 2024
Updated On : 28 Jun 2022 | 11:20 PM IST

Cash-flush Novartis launches new share buyback of up to $15 bn

The buyback is funded through the $20.7 billion the Swiss drugmaker raised by selling its nearly one-third voting stake in Roche back to its cross-town rival last month

Cash-flush Novartis launches new share buyback of up to $15 bn
Updated On : 16 Dec 2021 | 2:41 PM IST

Novartis cuts uneasy 20-year ties to Roche with $20.7-bn voting stake sale

The company is booking a capital gain of about $14 billion on the investment at a time when the cost of acquisitions in pharma have been soaring

Novartis cuts uneasy 20-year ties to Roche with $20.7-bn voting stake sale
Updated On : 05 Nov 2021 | 12:37 AM IST

Novartis Q1 sales, profit miss analyst expectations amid Covid-19 impact

Swiss drugmaker Novartis on Tuesday said first-quarter core net income fell 4%

Novartis Q1 sales, profit miss analyst expectations amid Covid-19 impact
Updated On : 27 Apr 2021 | 3:11 PM IST

Novartis, Molecular Partner team up on coronavirus candidates treatment

Novartis has licenced global rights to two Molecular Partners antiviral drugs that have potential to treat Covid-19 patients, the two companies said

Novartis, Molecular Partner team up on coronavirus candidates treatment
Updated On : 28 Oct 2020 | 12:48 PM IST

Novartis lifts 2020 forecast as drugmakers see hospitals coping with Covid

ZURICH (Reuters) - Novartis joined rivals Merck, Johnson & Johnson and Roche in predicting the worst of the pandemic may be over for drugmakers, amid signs healthcare systems have learned how to cope with surging infections without shutting down all services.

Novartis lifts 2020 forecast as drugmakers see hospitals coping with Covid
Updated On : 27 Oct 2020 | 9:00 PM IST
Updated On : 02 Jul 2020 | 5:16 PM IST

Novartis pays $729 mn to settle US charges that it paid doctors kickbacks

It will also pay $51.25 million to resolve charges it funnelled money through three charitable foundations to cover co-payments of Medicare patients so they would purchase its drugs

Novartis pays $729 mn to settle US charges that it paid doctors kickbacks
Updated On : 02 Jul 2020 | 1:17 PM IST

Coronavirus vaccine not coming for at least 2 years: Novartis global CEO

A vaccine must be widely tested in humans before being administered to hundreds of millions, say experts

Coronavirus vaccine not coming for at least 2 years: Novartis global CEO
Updated On : 16 May 2020 | 3:54 AM IST

Novartis confirms 2020 outlook; sales, profit up amid Covid-19 outbreak

Core net income rises to $3.55 billion from $2.8 billion in 2019, against the average analyst forecast in a Refinitiv poll of $3.17 billion

Novartis confirms 2020 outlook; sales, profit up amid Covid-19 outbreak
Updated On : 28 Apr 2020 | 8:03 PM IST

Novartis scraps sale of assets including Covid-19 drug to Aurobindo Pharma

Novartis is donating 130 million hydroxychloroquine doses to support efforts against the epidemic, though the European Union has so far said there is no proof it works.

Novartis scraps sale of assets including Covid-19 drug to Aurobindo Pharma
Updated On : 09 Apr 2020 | 7:26 AM IST

Novartis CEO says Malaria drug biggest hope against coronavirus: Newspaper

Malaria, lupus and arthritis drug hydroxychloroquine is under clinical trials, says Novartis.

Novartis CEO says Malaria drug biggest hope against coronavirus: Newspaper
Updated On : 29 Mar 2020 | 2:28 PM IST